Servier Forschung-und-Pharma-Entwicklung and Clariness are partnering to advance a Phase II clinical trial for a new drug targeting primary Sjögren's syndrome. The trial aims to evaluate the efficacy of a novel biological therapy designed to suppress the inflammatory processes characteristic of the autoimmune disease.
Primary Sjögren’s syndrome is a systemic autoimmune disease that predominantly affects the salivary and lacrimal glands, leading to dry eyes and dry mouth. Worldwide, approximately 60 out of 100,000 individuals are affected by this condition. The collaboration between Servier and Clariness seeks to address the significant unmet medical need for targeted treatments for this disease.
"So far, there is no targeted treatment that has proven to be effective. Treatment is therefore individualised and depends on the type and extent of symptoms. Current treatment options mainly include the use of symptomatic agents such as tear and saliva substitutes, saliva stimulating substances and pain medication," states Servier. The investigational drug represents a potential advancement over existing symptomatic treatments.
The Phase II trial is currently underway, with Clariness supporting patient recruitment efforts in Germany through its ClinLife portal. "We are delighted to have signed our first contract with Servier Forschung-und-Pharma-Entwicklung for our ClinLife Registry product. We are providing patient recruitment support at various sites in Germany," said Moritz Kloss, vice-president of ClinLife Registry at Clariness. Patient recruitment commenced in the first quarter of 2022.
